Deer Antler Stem Cell Vesicles Reverse Bone Loss and Epigenetic Aging in Mice and Monkeys

Aging drives roughly 23% of the global disease burden, and researchers have increasingly focused on intercellular signaling factors—particularly from young or highly regenerative cells—as therapeutic candidates. Stem cell-derived extracellular vesicles (EVs) are attractive because they recapitulate donor cell benefits without the biosafety and ethical concerns of live cell transplantation. However, conventional mesenchymal stem cells (MSCs) from bone marrow, adipose, or umbilical cord tissue senesce after 10–15 culture passages, limiting both yield and potency of derived EVs.

This study introduces antler blastema progenitor cells (ABPCs) as a novel MSC source. ABPCs reside at the periosteum of regenerating deer antlers—the only mammalian organ capable of complete annual regeneration in adulthood, growing at up to 2.75 cm/day and producing up to 15 kg of bone within 3 months. Unlike bone marrow MSCs from aged or fetal rats, ABPCs showed 72.4% lower senescence-associated β-galactosidase activity, maintained robust osteogenic differentiation, and displayed no meaningful senescence markers even after 50 consecutive culture passages. Proteomic and small RNA profiling of ABPC-derived EVs (EVs^ABPC) revealed enrichment of unique regenerative proteins and microRNAs not found in conventional MSC-derived EVs, pointing to a distinct cargo signature likely underlying their potency.

In vitro, EVs^ABPC attenuated senescence phenotypes in aged bone marrow stem cells, reducing SA-β-gal activity, p21 and γ-H2AX expression, and shifting differentiation balance away from adipogenesis toward osteogenesis. Moving to animal models, aged mice receiving intravenous EVs^ABPC showed substantially increased femoral bone mineral density by microCT analysis, along with improved grip strength, endurance, and spatial cognitive performance in standardized behavioral assays. Systemic inflammatory markers were reduced, and DNA methylation-based epigenetic clocks indicated an age reversal of over 3 months relative to untreated aged controls.

Critically, the team extended these experiments to aged rhesus macaques (Macaca mulatta), a non-human primate model far closer to humans in physiology and aging trajectory. EV^ABPC treatment in macaques similarly increased bone mineral density, improved locomotor scores, reduced neuroinflammatory markers, and demonstrated neuroprotection in brain tissue assessments. Epigenetic age, measured via validated primate methylation clocks, was reduced by more than 2 years in treated animals—a striking magnitude for any single intervention. No significant adverse effects were reported in either model.

The authors position ABPCs as a scalable, ethically straightforward, and biologically exceptional EV source. Because antler tissue can be harvested annually without harm to the animal, and ABPCs expand indefinitely in culture without senescence, large-scale EV production is feasible. While results across two mammalian species are compelling, human clinical translation will require formal safety profiling, optimized dosing, and ultimately randomized controlled trials.